Circulating antigen: Bad or good for immunoscintigraphy?

https://doi.org/10.1016/0969-8051(94)00098-5Get rights and content

Abstract

There is ample evidence to show that circulating antigen can restrict effective localization of radiolabelled murine monoclonal antibodies in human tumours growing as xenografts in Nude mice. This is the result of the formation of immune complexes in the circulation. Surprisingly this effect is not seen in patients with circulating antigen, although immune complexes are formed in the circulation, and immunoscintigraphy is not compromised. Moreover, at least in some situations, the presence and level of circulating antigen correlates positively with the sensitivity of tumour imaging, and circulating antigen can be used as a criterion of patient selection for immunoscintigraphy. The reason for the dichotomy between mouse and man is unclear, and seems to be the subject of little or no current research. The introduction of chimeric or fully human monoclonal antibodies in place of murine monoclonal antibodies means that clinical situations will now mimic more precisely the animal models. The species of antibody complexing with antigen will be homologous to the patients, and this could result in handling of those complexes in a manner different from the handling of complexes with foreign (i.e. murine) antibodies. Clearly this subject warrants further investigation.

References (37)

  • MachJ-P. et al.

    Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy

    Immunology Today

    (1981)
  • PimmM.V. et al.

    Influence of circulating antigen on the biodistribution and tumour localization of radiolabelled monoclonal antibody in a human tumour:nude mouse xenograft model

    Eur. J. Cancer Clin. Oncol.

    (1989)
  • Abdel-NabiH.H. et al.

    Colorectal carcinoma: detection with indium-111 anti-carcinoembryonic-antigen monoclonal antibody ZCE-025

    Radiology

    (1987)
  • BeattyB.G. et al.

    Effect of specific antibody pretreatment on liver uptake of 111In-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing human colon cancer xenografts

    Cancer Res.

    (1989)
  • BosslettK. et al.

    Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas

    Eur. J. Nucl. Med.

    (1988)
  • CarrasquilloJ.A. et al.

    Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody

    J. Nucl. Med.

    (1988)
  • ColcherD. et al.

    Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients

    Cancer Res.

    (1987)
  • ColcherD. et al.

    In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer

    J. Nucl. Med.

    (1990)
  • DavidsonB.R. et al.

    The effect of circulating antigen and radiolabel stability on the biodistribution of an indium labelled antibody

    Br. J. Cancer

    (1991)
  • DavisQ. et al.

    Immunoscintigraphy of ovarian cancer using a CDR grafted antibody (hCTM01): first clinical results

  • DoerrR.J. et al.

    Radiolabeled antibody imaging in the management of colorectal cancer

    Annal. Surg.

    (1991)
  • DouillardJ-Y. et al.

    Pharmacokinetic study of radiolabeled anti-colorectal carcinoma monoclonal antibodies in tumour-bearing nude mice

    Eur. J. Nucl. Med.

    (1985)
  • DuewellS. et al.

    Uptake of a monoclonal antibody against CEA (Tumak 431/31) in a human colon tumor (Co-112) xenografted in the nude mouse

    Cancer Immunol. Immunother.

    (1986)
  • HaganP.L. et al.

    In vivo kinetics of radiolabeled monoclonal anti-CEA antibodies in animals models

    J. Nucl. Med.

    (1985)
  • HnatowichD.J. et al.

    Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients

    J. Nucl. Med.

    (1985)
  • HnatowichD.J. et al.

    Pharmacokinetics of 111In-labeled OC-125 antibody in cancer patients compared with the 19-9 antibody

    Cancer Res.

    (1987)
  • KhazaeliM.B. et al.

    Pharmacokinetics and immune response of131I-chimeric mouse/human B72.3 (human γ4) monoclonal antibody in humans

    Cancer Res.

    (1991)
  • LarsonS.M. et al.

    Imaging of melanoma with I-131-labeled monoclonal antibody

    J. Nucl. Med.

    (1983)
  • Cited by (21)

    • Evaluation of <sup>111</sup>In labeled antibodies for SPECT imaging of mesothelin expressing tumors

      2011, Nuclear Medicine and Biology
      Citation Excerpt :

      Prior studies in human patients injected with radiolabeled antibodies against carcinoembryonic antigen (CEA) have shown that although there is formation of immune complexes with the circulating antigens, the localization of activity into the tumors remains unaffected and there is no marked clearance of the radiolabel in the liver or the spleen. As a result, tumor detection by γ-immunoscintigraphy remained unaffected [42]. Nonetheless, if spleen uptake of 111In-mAbMB is observed in human patients, pre-administration of unlabeled mAbMB may be used as a strategy to reduce the spleen uptake.

    View all citing articles on Scopus
    View full text